[
  {
    "ts": null,
    "headline": "iShares Select Dividend Fund Has A Surprisingly High Yield For Retirees",
    "summary": "The iShares Select Dividend ETF (NYSEARCA:DVY) has become a cornerstone holding for income-focused retirees seeking reliable dividend income. With a yield of 3.61%, the fund delivers nearly triple the S&P 500’s yield while maintaining exposure to 100 dividend-paying U.S. equities. The ETF’s appeal extends beyond yield alone: DVY appreciated 13% over the past year, delivering ... iShares Select Dividend Fund Has A Surprisingly High Yield For Retirees",
    "url": "https://finnhub.io/api/news?id=502e1c91150632d3af9bfa52404525e9f7d72fb1083b25d057899c7d162a2e02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767715678,
      "headline": "iShares Select Dividend Fund Has A Surprisingly High Yield For Retirees",
      "id": 138002064,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The iShares Select Dividend ETF (NYSEARCA:DVY) has become a cornerstone holding for income-focused retirees seeking reliable dividend income. With a yield of 3.61%, the fund delivers nearly triple the S&P 500’s yield while maintaining exposure to 100 dividend-paying U.S. equities. The ETF’s appeal extends beyond yield alone: DVY appreciated 13% over the past year, delivering ... iShares Select Dividend Fund Has A Surprisingly High Yield For Retirees",
      "url": "https://finnhub.io/api/news?id=502e1c91150632d3af9bfa52404525e9f7d72fb1083b25d057899c7d162a2e02"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=51894ff71f7dcafac9f709277e4d727ae0be5c49ff7c1a8dfd82ab5981733c8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708005,
      "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
      "id": 138002065,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=51894ff71f7dcafac9f709277e4d727ae0be5c49ff7c1a8dfd82ab5981733c8d"
    }
  },
  {
    "ts": null,
    "headline": "Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens",
    "summary": "SOUTH SAN FRANCISCO, Calif., January 06, 2026--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced a strategic collaboration with Pfizer to discover tumor-selective antigens. Under the multi-year agreement, Cartography will apply its proprietary ATLAS and SUMMIT discovery platforms to identify and validate tumor-selective antigens in an undisclosed indication. Pfizer may opt in on multiple antigens identif",
    "url": "https://finnhub.io/api/news?id=eefe59b275e552e5eb547191bef53d8f1cc655253fd3f80b7af2ae5cd253ed24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767702600,
      "headline": "Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens",
      "id": 137999418,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SOUTH SAN FRANCISCO, Calif., January 06, 2026--Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced a strategic collaboration with Pfizer to discover tumor-selective antigens. Under the multi-year agreement, Cartography will apply its proprietary ATLAS and SUMMIT discovery platforms to identify and validate tumor-selective antigens in an undisclosed indication. Pfizer may opt in on multiple antigens identif",
      "url": "https://finnhub.io/api/news?id=eefe59b275e552e5eb547191bef53d8f1cc655253fd3f80b7af2ae5cd253ed24"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Quarterly Earnings Preview: What You Need to Know",
    "summary": "Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.",
    "url": "https://finnhub.io/api/news?id=5f1126ef06862546753b3d10071026e912d1dcf28f7ed0617b7848f5b7006f08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767699798,
      "headline": "Pfizer's Quarterly Earnings Preview: What You Need to Know",
      "id": 138000630,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.",
      "url": "https://finnhub.io/api/news?id=5f1126ef06862546753b3d10071026e912d1dcf28f7ed0617b7848f5b7006f08"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Wegovy Pill Is Not A Game Changer",
    "summary": "Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline is weak. See why NVO stock is a Hold now.",
    "url": "https://finnhub.io/api/news?id=ed9347c7022616b3f53ba7da81433e024670b0910213a9ea223533564994b734",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767693600,
      "headline": "Novo Nordisk: Wegovy Pill Is Not A Game Changer",
      "id": 138000775,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1675157246/image_1675157246.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline is weak. See why NVO stock is a Hold now.",
      "url": "https://finnhub.io/api/news?id=ed9347c7022616b3f53ba7da81433e024670b0910213a9ea223533564994b734"
    }
  },
  {
    "ts": null,
    "headline": "2 S&P 500 Stocks with Competitive Advantages and 1 We Avoid",
    "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
    "url": "https://finnhub.io/api/news?id=e3493b3c9f86c9d3ab9c5820b10acf5c67eab7ae394e119ad0096b7653c56e2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767674055,
      "headline": "2 S&P 500 Stocks with Competitive Advantages and 1 We Avoid",
      "id": 137999419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
      "url": "https://finnhub.io/api/news?id=e3493b3c9f86c9d3ab9c5820b10acf5c67eab7ae394e119ad0096b7653c56e2a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals",
    "summary": "Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer Inc. (NYSE:PFE) is among the drugmakers planning to raise prices on some medicines starting January 1. The increases will affect about 350 drugs, even as President Donald Trump has reached agreements with 14 pharmaceutical companies to lower prices on […]",
    "url": "https://finnhub.io/api/news?id=49190c4a590cfe24f2612487d95d0ec2021cca583e317476ed9f7e46bcf15637",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767668436,
      "headline": "Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals",
      "id": 137997878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer Inc. (NYSE:PFE) is among the drugmakers planning to raise prices on some medicines starting January 1. The increases will affect about 350 drugs, even as President Donald Trump has reached agreements with 14 pharmaceutical companies to lower prices on […]",
      "url": "https://finnhub.io/api/news?id=49190c4a590cfe24f2612487d95d0ec2021cca583e317476ed9f7e46bcf15637"
    }
  }
]